Jade Biosciences has secured USD 80 million in a Series A funding round co-led by Fairmount and Venrock Healthcare Capital Partners, with participation from Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments, and Braidwell LP.

The company plans to use these funds to develop targeted therapies for inflammation and immunology.

Jade Biosciences specializes in mass spectrometry-based proteomics services, with preparation methods that cater to all biological sample types, including cells, animal and plant tissues, biofluids, and environmental and microbial samples. Its mass spectrometry platforms provide deep proteome coverage, enabling the detection of post-translational modifications, such as phosphorylation and acetylation. It offers precise relative and absolute protein quantitation in genome-wide and targeted discovery modes.

Analyst QuickTake: Jade Biosciences is the fourth company launched by Paragon Therapeutics. Other companies previously launched (spin-outs) include Apogee Therapeutics , Spyre Therapeutics , and Oruka Therapeutics, The company continues to develop therapies through various avenues, including the creation of new companies, strategic partnerships, and the development of in-house programs.